Fibrocell Science (NASDAQ:FCSC) Downgraded by ValuEngine

ValuEngine downgraded shares of Fibrocell Science (NASDAQ:FCSC) from a hold rating to a sell rating in a research report report published on Saturday, ValuEngine reports.

Other equities research analysts have also recently issued research reports about the company. Zacks Investment Research cut Fibrocell Science from a buy rating to a hold rating in a research note on Tuesday, June 18th. HC Wainwright restated a buy rating and set a $22.00 target price on shares of Fibrocell Science in a research note on Thursday, March 28th.

FCSC stock opened at $1.91 on Friday. The stock’s 50 day simple moving average is $1.97. The stock has a market capitalization of $19.33 million, a PE ratio of -1.32 and a beta of 1.75. Fibrocell Science has a fifty-two week low of $1.45 and a fifty-two week high of $3.36. The company has a debt-to-equity ratio of 0.85, a quick ratio of 3.59 and a current ratio of 3.59.

Fibrocell Science (NASDAQ:FCSC) last posted its earnings results on Wednesday, May 15th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.07). Research analysts predict that Fibrocell Science will post -1.31 EPS for the current fiscal year.

A hedge fund recently bought a new stake in Fibrocell Science stock. Apis Capital Advisors LLC acquired a new stake in Fibrocell Science Inc (NASDAQ:FCSC) in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 25,000 shares of the company’s stock, valued at approximately $48,000. Apis Capital Advisors LLC owned about 0.26% of Fibrocell Science at the end of the most recent quarter. 28.04% of the stock is currently owned by institutional investors and hedge funds.

About Fibrocell Science

Fibrocell Science, Inc, an autologous cell and gene therapy company, focuses on discovering and developing therapies for diseases affecting the skin and connective tissues in the United States. The company's gene therapy product candidates include FCX-007 that is in Phase I/II clinical trials to treat recessive dystrophic epidermolysis bullosa; FCX-013, a gene therapy for localized scleroderma; and gene-therapy program that is in research phase to arthritis and related conditions.

Recommended Story: The mechanics of the bid-ask spread in trading

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Fibrocell Science Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fibrocell Science and related companies with's FREE daily email newsletter.